# Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

> **NCT05879653** · PHASE2 · RECRUITING · sponsor: **Kyoto University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** MK-3475
- **DRUG:** ASG-22CE
- **PROCEDURE:** maximal TURBT
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT05879653
- **Lead sponsor:** Kyoto University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05879653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05879653, "Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05879653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*